[go: up one dir, main page]

SU1666116A1 - Method for treatment of trifacial neuralgia - Google Patents

Method for treatment of trifacial neuralgia Download PDF

Info

Publication number
SU1666116A1
SU1666116A1 SU894667447A SU4667447A SU1666116A1 SU 1666116 A1 SU1666116 A1 SU 1666116A1 SU 894667447 A SU894667447 A SU 894667447A SU 4667447 A SU4667447 A SU 4667447A SU 1666116 A1 SU1666116 A1 SU 1666116A1
Authority
SU
USSR - Soviet Union
Prior art keywords
branch
myelopid
neuralgia
patient
treatment
Prior art date
Application number
SU894667447A
Other languages
Russian (ru)
Inventor
Михаил Никифорович Пузин
Александр Владимирович Кулаков
Владимир Дмитриевич Прокопенко
Original Assignee
Московский медицинский стоматологический институт им.Н.А.Семашко
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Московский медицинский стоматологический институт им.Н.А.Семашко filed Critical Московский медицинский стоматологический институт им.Н.А.Семашко
Priority to SU894667447A priority Critical patent/SU1666116A1/en
Application granted granted Critical
Publication of SU1666116A1 publication Critical patent/SU1666116A1/en

Links

Landscapes

  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относитс  к области медицины, а именно к неврологии. Способ позвол ет сократить сроки лечени , что достигаетс  назначением препаратов группы карбамазепина и дополнительно иммуномодулирующего препарата - миелопида.This invention relates to the field of medicine, namely to neurology. The method makes it possible to shorten the treatment time, which is achieved by prescribing drugs of the carbamazepine group and, additionally, an immunomodulating drug, myelopid.

Description

Изобретение относитс  к медицине, а именно к неврологии.The invention relates to medicine, namely to neurology.

Цель изобретени  - сокращение сроков лечени .The purpose of the invention is to reduce the duration of treatment.

Способ осуществл ют следующим образом .The method is carried out as follows.

Больному назначают лечение препаратами карбамазепина 0,1x2 раза в день и дополнительно миелопид в виде подкожных инъекций, которые готов т extempore в дозе 0,002-0,004 г на 1 см3 физиологического рартвора. Миелопид ввод т через день, курс лечени  4-5 инъекций.The patient is prescribed treatment with carbamazepine 0.1x2 times a day and additionally mielopid in the form of subcutaneous injections, which is prepared extempore at a dose of 0.002-0.004 g per 1 cm3 of physiological solution. Myelopid is administered every other day, a course of treatment is 4-5 injections.

Claims (1)

Пример. Больной В., 50 лет, госпитализирован с жалобами на посто нные боли в области нижней челюсти справа. Диагноз: одоНтогенна  невралги  111 ветви Vчерепно- мозгового нерва справа. В ходе обследовани  была вы влена болезненность при пальпации точки выхода ветви тройничного нерва справа в зоне иннервации этой ветви. Проведен курс лечени  по предлагаемому способу: финлепсин 0,1x2 раза в день в сочетании с 0,002-0,004 г миелопида на 1 см3 физиологического раствора через день. Проведено 5 подкожных инъекций. Через 12 дней больной выписан под наблюдение врача районной поликлиники в хорошем состо нии И приступил к трудовой де тельности. Формула изобретени  Способ лечени  невралгии тройничного нерва, включающий введение препаратов группы карбамазепина,отличающийс  тем, что, с целью сокращени  сроков лечени , дополнительно ввод т иммуномодулирую- щий препарат - миелопид.Example. Patient V., 50 years old, was hospitalized with complaints of persistent pain in the lower jaw to the right. Diagnosis: single neuralgia 111 of the branch of the V craniocerebral nerve on the right. During the examination, pain was found on palpation of the exit point of the trigeminal branch on the right in the innervation zone of this branch. A course of treatment according to the proposed method was carried out: finlepsin 0.1x2 times per day in combination with 0.002-0.004 g of myelopid per 1 cm3 of saline solution every other day. Conducted 5 subcutaneous injections. After 12 days, the patient was discharged under the supervision of a doctor of the district polyclinic in good condition, and began to work. The invention The method of treating trigeminal neuralgia, including the administration of drugs of the carbamazepine group, characterized in that, in order to shorten the treatment time, an immunomodulating drug, myelopid, is further administered. -5-five fefe ОABOUT о (about ( схsc
SU894667447A 1989-04-05 1989-04-05 Method for treatment of trifacial neuralgia SU1666116A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SU894667447A SU1666116A1 (en) 1989-04-05 1989-04-05 Method for treatment of trifacial neuralgia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU894667447A SU1666116A1 (en) 1989-04-05 1989-04-05 Method for treatment of trifacial neuralgia

Publications (1)

Publication Number Publication Date
SU1666116A1 true SU1666116A1 (en) 1991-07-30

Family

ID=21436521

Family Applications (1)

Application Number Title Priority Date Filing Date
SU894667447A SU1666116A1 (en) 1989-04-05 1989-04-05 Method for treatment of trifacial neuralgia

Country Status (1)

Country Link
SU (1) SU1666116A1 (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Карлов В.А. Терапи нервных болезней. М.: Медицина. 1987, с. 473-478. *

Similar Documents

Publication Publication Date Title
Di Chiara et al. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.
Kaji et al. Effect of ultrahigh‐dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: A double‐blind controlled study
RU2001116077A (en) A method for the treatment of cerebral ischemia, as well as the use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischemia
DE69230112D1 (en) ADVANCED DRUG DELIVERY SYSTEM AND METHOD FOR TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISEASES WITH CARBAMAZEPINE
Walker et al. Complex regional pain syndromes: including “reflex sympathetic dystrophy” and “causalgia”
SU1666116A1 (en) Method for treatment of trifacial neuralgia
ES2159661T3 (en) USE OF A MUSCARINIC ANTAGONIST FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT AND CONTROL OF EYE DEVELOPMENT.
Wood et al. Trial of aspirin and RA 233 in prevention of post-operative deep vein thrombosis
Brezenoff et al. The actions of polymyxin B and histamine on ganglionic transmission
Cohen et al. The anticonvulsant action of dilantin on sound-induced seizures in the rat.
BG62759B1 (en) ANIMAL AND METHOD FOR TREATMENT OF AUTOMMUNE DISEASES
RU1822775C (en) Method for treatment of trigeminal nerve neuralgia
RU2000789C1 (en) Analgetic
Goodman et al. Anticonvulsant Properties of 5, 5-Phenyl Thienyl Hydantoin in Comparison with Dilantin and Mesantion.
RU2005459C1 (en) Method for treating endocrine sterility in women
Kapoor et al. Myoclonic epilepsy in an HIV positive patient: neurophysiological findings
Gerst et al. Lithium-induced improvement of myotonia
Funcke et al. Protective action of cyclandelate in hypoxia
SU1553064A1 (en) Method of anesthetizing at treating teeth and jaws
SU1560214A1 (en) Method of treating phantom limb pain
SU1487907A1 (en) Method of treating ovular paints
COPPEN The role of lithium carbonate in the treatment and prophylaxis of the affective disorders
Bisgaard Further Contributions to the Problem of the Function of the Parathyroid Glands and the Pathogenesis of true Epilepsy
SU1364340A1 (en) Method of treatment of chronic glomerulonephritis complicated with nephrotic syndrome
RU2144364C1 (en) Method of treatment of patient with limb lymphedema